Biocept, Inc. (BIOC)
Seite 17 von 19 Neuester Beitrag: 09.09.23 08:09 | ||||
| Eröffnet am: | 21.03.18 12:19 | von: Chalifmann3 | Anzahl Beiträge: | 453 |
| Neuester Beitrag: | 09.09.23 08:09 | von: johnnie11 | Leser gesamt: | 100.779 |
| Forum: | Hot-Stocks | Leser heute: | 90 | |
| Bewertet mit: |  | |||
| Seite: < 1 | ... | 13 | 14 | 15 | 16 | | 18 | 19 > | ||||
Biocept Reports 2019 Fourth Quarter and Full Year Financial Results
Alert
Biocept (NASDAQ:BIOC)
Intraday Stock Chart
Today : Wednesday 25 March 2020
Click Here for more Biocept Charts.
SAN DIEGO, March 25, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the three and 12 months ended December 31, 2019, and provides an update on its business progress.
Biocept Logo (PRNewsFoto/Biocept, Inc.)
"I'm pleased to report our sixth consecutive quarter of growth with fourth quarter revenues reaching a record $1.8 million, more than double the prior year's quarterly revenues," said Michael Nall, President and CEO of Biocept. "Our growth for the quarter was driven by year-over-year increases of 46% in commercial test volume and 34% in average reimbursement per patient, predominantly due to reporting on more tests per accession ordered by referring doctors. While growing revenues, we also benefitted from operating efficiencies, including automation initiatives in our CLIA-certified laboratory. These efficiencies combined with higher sample volume moved us significantly closer to positive gross margin. We have more actions to complete the automation of our lab and we are pleased with the contribution from these efforts so far.
"Revenue for the full year 2019 increased 70% over the prior year," said Mr. Nall. "A key growth driver throughout 2019 was our decision to focus on prostate cancer, including committing more commercial resources to urologists and urology practices and introducing additional prognostic and predictive biomarker tests. As the year progressed, we were encouraged that more urologists were using more biomarkers per test for more of their patients.
"I'm exceptionally proud of our strong operational performance throughout 2019 and into 2020. Among notable accomplishments, we launched the first-and-only liquid biopsy test to evaluate cerebrospinal fluid as well as NGS test panels for lung and breast cancer. We also added a new revenue stream from sales of our Target Selector™ research-use only (RUO) kits, further expanded our intellectual property portfolio with new U.S. and foreign patents, and presented compelling data further validating our technology at multiple scientific conferences and in peer-reviewed journals," he added. "So far this year, we have raised net proceeds of $17.5 million from two equity offerings and warrant exercises, positioning us for continued execution on our growth strategy."
2019 and Recent Highlights
Commercial Launches
Announced the availability of Target Selector™ assays to evaluate cerebrospinal fluid (CSF) for the presence of circulating tumor cells (CTCs) and biomarkers, which may be indicators of brain metastases. Of patients diagnosed with breast and lung cancer, 30% and 36%, respectively, will develop brain metastases. The validations study for the CSF assay was conducted in collaboration with Providence St. Joseph Health, Southern California, and its wholly owned affiliates Providence St. John's Health Center and John Wayne Cancer Institute.
Launched Target Selector™ NGS Lung Panel and Target Selector™ NGS Breast Panel, the Company's first two multi-gene liquid biopsy panels, differentiating Biocept as the only commercial liquid biopsy provider of single-biomarker testing, tumor-specific panels and CTC analysis. The NGS Panels run on Thermo Fisher Scientific's Ion Torrent™ NGS platform and are being marketed to physicians and researchers for the detection and monitoring of actionable biomarkers associated with these tumor-specific cancers.
Launched Target Selector™ pan-TRK assay for the detection of TRK proteins, which are actionable biomarkers that can be used to qualify patients for treatment with TRK inhibitor therapies. The pan-TRK assay, which utilizes Biocept's proprietary CTC platform to screen for TRK gene alternations, is a unique liquid biopsy offering.
Launched expanded pathology partnership service, EmpowerTC™, with additional prognostic and predictive biomarker tests to enable urology and uropathology practices to perform liquid biopsy testing and interpret results generated in Biocept's CLIA-certified laboratory.
Announced the availability of RUO kits, which enable molecular laboratories around the world to utilize Target Selector™ circulating tumor DNA (ctDNA) assays to perform liquid biopsy testing. Also announced an agreement with Agiomix FZ-LLC, a provider of genomics sample and bioinformatics services for research and clinical applications, to validate and purchase Biocept's Target Selector™ RUO kits for use in its laboratory.
Commercial Agreements
Announced an agreement with Beacon Laboratory Benefit Solutions designating Biocept as a BeaconLBS® Lab-of-Choice, increasing patient access to Biocept' liquid biopsy testing platforms. Beacon Laboratory is a nationally recognized provider of laboratory benefit management technology solutions to U.S.-based health and managed care companies.
Signed an agreement with a large California-based independent physician association (IPA) to provide Biocept's Target Selector™ liquid biopsy testing services to physicians and patients in their network.
Regulatory Approval
Obtained CE IVD Marks for the CEE-Sure® Blood Collection Tube and the CEE-Sure® Sample Collection Shipping Kit in Europe. These CE Marks confirm that Biocept's CEE-Sure® products, which are specifically designed to collect and transport blood and other liquid biopsy specimens, meet the requirements of the European In-Vitro Diagnostic Devices Directive. These clearances allow Biocept to commercialize its tubes and collection/shipping kits throughout the European Union and other CE Mark geographies.
Industry Conference Presentations
Presented six posters at the 2019 Association for Molecular Pathology (AMP) Annual Meeting featuring clinical data highlighting Target Selector™ tests and kits. The content of these posters will be published in a future issue of The Journal of Molecular Diagnostics.
Presented data at the 2019 IASLC World Conference on Lung Cancer highlighting the ability of Biocept's circulating tumor DNA (ctDNA) assays to consistently detect actionable biomarkers from the blood of patients diagnosed with lung cancer at a mutant allele frequency as low as 0.01%. The poster featured data from more than 1,400 blood samples drawn from patients diagnosed with non-small cell lung cancer, and collected and shipped using the Company's CEE-Sure® Blood Collection Tubes.
Presented a poster at the 2019 American Association for Cancer Research Annual Meeting demonstrating the ability of the Target Selector™ assay to detect ESR1 mutations with high sensitivity, resulting in inclusion of the test in a clinical trial sponsored by a major pharmaceutical company.
Presented a poster at the 2019 San Antonio Breast Cancer Symposium® demonstrating the ability of the Target Selector™ CTC platform to aid in the monitoring and treatment of breast cancer. Study results demonstrated the platform's ability to accurately detect, enumerate and interrogate CTCs in a cohort of more than 1,500 patients, representing various clinical and treatment stages of breast cancer.......
Biocept Enters into Laboratory Services Agreement with Second California-Based Independent Physician Association
Alert
Biocept (NASDAQ:BIOC)
Intraday Stock Chart
Today : Thursday 26 March 2020
Click Here for more Biocept Charts.
SAN DIEGO, March 26, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has entered into an agreement with a second California-based independent physician association (IPA) to provide its Target Selector™ liquid biopsy assay services to physicians and patients in their network. Biocept's Target Selector™ offering includes the choice of individual biomarker tests or a larger liquid biopsy panel, enabling physicians to select the best approach for each patient.
Biocept Logo (PRNewsFoto/Biocept, Inc.)
"We are pleased to reach an agreement with a second large California-based IPA, this one in the southern part of the state, to provide liquid biopsy services for patients diagnosed with cancer," said Michael Nall, Biocept's President and CEO. "Our offerings provide evidence-based, clinically actionable results in a timely and cost-effective manner. This approach has been resonating with IPAs, ACOs, HMOs and other value-oriented stakeholders alike, and we look forward to further expanding our reach within our home state of California."
About Biocept
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in plasma (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of patients diagnosed with cancer and the expansion in the number of patients that will have an opportunity to benefit from our liquid biopsy testing platforms, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at http://www.sec.gov.
Contact:
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100
Media:
CORE IR:
Jules Abraham
julesa@coreir.com
917-885-7378
Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/...association-301030077.html
SOURCE Biocept, Inc.
https://ih.advfn.com/stock-market/NASDAQ/...ratory-services-agreement
Biocept schließt mit der zweiten unabhängigen Ärztevereinigung in Kalifornien einen Vertrag über Labordienstleistungen ab
Warnen
Biocept (NASDAQ: BIOC)
Intraday-Aktienchart
Heute: Donnerstag, 26. März 2020
Klicken Sie hier für weitere Biocept-Diagramme.
San Diego, 26. März 2020 (ots / PRNewswire) - Biocept, Inc. (Nasdaq: BIOC), ein führender kommerzieller Anbieter von Flüssigkeitsbiopsietests, der Ärzten klinisch umsetzbare Informationen zur Verbesserung der Ergebnisse von Krebspatienten liefern soll, gibt dies bekannt Das Unternehmen hat mit einer zweiten in Kalifornien ansässigen unabhängigen Ärztevereinigung (IPA) eine Vereinbarung getroffen, um Ärzten und Patienten in ihrem Netzwerk seine Target Selector ™ -Liqui-Biopsie-Assay-Dienste anzubieten. Das Target Selector ™ -Angebot von Biocept umfasst die Auswahl einzelner Biomarker-Tests oder eines größeren Flüssigkeitsbiopsie-Panels, sodass Ärzte für jeden Patienten den besten Ansatz auswählen können.
Biocept-Logo (PRNewsFoto / Biocept, Inc.)
"Wir freuen uns, mit einer zweiten großen IPA in Kalifornien, die sich im südlichen Teil des Bundesstaates befindet, eine Vereinbarung über die Bereitstellung von Flüssigbiopsiediensten für Patienten mit Krebsdiagnose zu treffen", sagte Michael Nall, President und CEO von Biocept. "Unsere Angebote liefern zeitnahe und kostengünstige evidenzbasierte, klinisch umsetzbare Ergebnisse. Dieser Ansatz hat bei IPAs, ACOs, HMOs und anderen wertorientierten Stakeholdern gleichermaßen Anklang gefunden, und wir freuen uns darauf, unsere Reichweite innerhalb unserer Reichweite weiter auszubauen Heimatstaat Kalifornien. "
Über Biocept
Biocept, Inc. ist ein Unternehmen für Molekulardiagnostik mit kommerzialisierten Tests für Lungen-, Brust-, Magen-, Darm- und Prostatakrebs sowie Melanome. Das Unternehmen nutzt seine firmeneigene Flüssigbiopsietechnologie, um Ärzten Informationen zur Behandlung und Überwachung von Patienten mit Krebsdiagnose zur Verfügung zu stellen. Die patentierte Target Biector-Technologieplattform Target Selector ™ des Unternehmens erfasst und analysiert tumorassoziierte molekulare Marker sowohl in zirkulierenden Tumorzellen (CTCs) als auch in Plasma (ctDNA). Mit Tausenden von durchgeführten Tests hat die Plattform die Fähigkeit demonstriert, Krebsmutationen und -veränderungen zu identifizieren, um Ärzte über die Krankheit eines Patienten und die therapeutischen Möglichkeiten zu informieren. Weitere Informationen finden Sie unter www.biocept.com.
Zukunftsgerichtete Aussagen Haftungsausschluss
Diese Pressemitteilung enthält zukunftsgerichtete Aussagen, die auf aktuellen Erwartungen oder Überzeugungen beruhen, sowie eine Reihe von Annahmen über zukünftige Ereignisse. Obwohl wir der Ansicht sind, dass die in den zukunftsgerichteten Aussagen enthaltenen Erwartungen und die ihnen zugrunde liegenden Annahmen angemessen sind, können wir nicht garantieren, dass sich diese Erwartungen und Annahmen als richtig erweisen. Zukunftsgerichtete Aussagen sind im Allgemeinen durch die Verwendung von Wörtern wie "kann", "wird", "sollte", "könnte", "erwarten", "antizipieren", "schätzen", "glauben", "beabsichtigen" oder "identifizierbar" erkennbar "Projekt" oder das Negativ dieser Wörter oder andere Variationen dieser Wörter oder eine vergleichbare Terminologie. In dem Maße, in dem die Aussagen in dieser Pressemitteilung nicht streng historisch sind, einschließlich ohne Einschränkung Aussagen über unsere Fähigkeit, die Ergebnisse von Patienten mit Krebsdiagnose zu verbessern, und die Zunahme der Anzahl von Patienten, die die Möglichkeit haben, von unseren Flüssigkeitsbiopsietests zu profitieren Auf Plattformen sind solche Aussagen zukunftsgerichtet und werden gemäß den Safe-Harbor-Bestimmungen des Private Securities Litigation Reform Act von 1995 abgegeben. Der Leser wird darauf hingewiesen, sich nicht unangemessen auf diese zukunftsgerichteten Aussagen zu verlassen, da diese Aussagen unterliegen Zahlreiche Risikofaktoren, wie in unseren Unterlagen zur Securities and Exchange Commission (SEC) dargelegt. Die Auswirkungen solcher Risiken und Ungewissheiten können dazu führen, dass die tatsächlichen Ergebnisse erheblich von den in dieser Pressemitteilung enthaltenen zukunftsgerichteten Aussagen abweichen. Wir planen nicht, solche zukunftsgerichteten Aussagen zu aktualisieren und lehnen ausdrücklich jede Verpflichtung zur Aktualisierung der in dieser Pressemitteilung enthaltenen Informationen ab, es sei denn, dies ist gesetzlich vorgeschrieben. Den Lesern wird empfohlen, unsere Unterlagen bei der SEC zu überprüfen, auf die über das Internet auf der Website der SEC unter http://www.sec.gov zugegriffen werden kann.
Kontakt:
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100
Medien:
KERN IR:
Jules Abraham
julesa@coreir.com
917-885-7378
Cision Zeigen Sie den Originalinhalt an, um Multimedia herunterzuladen: http: //www.prnewswire.com/news-releases/...-physician-association-301030077. html
QUELLE Biocept, Inc.
https://ih.advfn.com/stock-market/NASDAQ/...ratory-services-agreement
weiß jemand, warum es hier gerade so stark nach oben geht?
https://old.nasdaq.com/de/symbol/bioc/real-time
https://biocept.com/covid-19/
Hier hat aber jemand die Kopie eingestellt:
https://web.archive.org/web/20200409180327/biocept.com/covid-19/
FDA Seite steht es nicht als approved in der Liste.
https://www.fda.gov/medical-devices/...-use-authorizations#covid19ivd
Mag sein, dass es stimmt mit FDA-approved. Würde aber auch in Betracht ziehen, dass das ein Fake war. Eventuell auch gar nicht von BIOC selbst verursacht.
Sag ja, die Seite war von Dritten verursacht. Einfach nicht beachten sagen sie.
;-)
In preparation to offer COVID-19 testing, an unapproved version of a test website page was inadvertently posted to the Company's website by a third-party website consultant. This unapproved test website page contained certain inaccuracies related to billing matters and should be disregarded.
Ein Pump vor dem Herren würde ich mal sagen. Die verwenden Tests von TF. Testauswertungen in ihrem eigenen Labor.
The lab will be using the FDA-approved for EUA (Emergency Use Authorization) testing ThermoFisher Scientific's TaqPath™ molecular diagnostic platform and kit for SARS-CoV-2 (COVID-19).
Also nix eigener FDA Approved Test-Kit.
https://finance.yahoo.com/news/...gin-covid-19-testing-231700864.html
Bleibe bei meinen 9 Cent PT.
Mit dieser Aktie hätte ich das ganze Minus seit Corona wettmachen und sogar ein bisschen ins Plus gehen können. Aber ich musste ja voreilig verkaufen. 
Hoffentlich rettet Aytu mich da jetzt raus, hahaha.
Insgesamt spiegelt der Kursverlauf gestern genau die Abläufe um den Covid 19 Teil der Biocept Webseite vom 09.04. wieder. Nicht sehr vertrauenserweckend für mich.
Warum geht der Link von der Biocept Website eigentlich direkt auf die Verkaufsseite von TF? Vielleicht weil Biocept nur die TF Tests auswerten kann, wenn sie einer kauft und zu Biocept zur Auswertung schickt?
https://biocept.com/covid-19/
https://www.thermofisher.com/us/en/home/clinical/...html?icid=WB44098
Der Zock geht weiter. ;-)
Und wo steht der Kurs heute , ja richtig ging gen Süden runter auf aktuell 0,43x, war ja klar dass man hier wieder nur abzocken wollte.